Sage Therapeutics, Inc.

SAGE

US78667J1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 16/07/2024 am IST			5-day change	1st Jan Change
11.8 ^USD	+0.34%		+7.86%	-45.55%

12/07	JPMorgan Lowers Price Target on Sage Therapeutics to $18 From $23, Maintains Overweight Rating	MT
09/07	RBC Cuts Price Target on Sage Therapeutics to $12 From $15, Keeps Sector Perform Rating	MT

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 3000 Growth Index

July 01, 2024

Latest news about Sage Therapeutics, Inc.

JPMorgan Lowers Price Target on Sage Therapeutics to $18 From $23, Maintains Overweight Rating	12/07	MT
RBC Cuts Price Target on Sage Therapeutics to $12 From $15, Keeps Sector Perform Rating	09/07	MT
Lantheus Holdings, Inc. Appoints Jamie Spaeth as Chief People Officer	08/07	CI
Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 3000E Growth Index	01/07	CI
Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 2000 Growth Index	01/07	CI
Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 3000 Growth Index	01/07	CI
Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell Small Cap Comp Growth Index	01/07	CI
Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 2500 Growth Index	01/07	CI
JPMorgan Adjusts Price Target on Sage Therapeutics to $23 From $28, Maintains Overweight Rating	20/06	MT
Transcript : Sage Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 02:00 PM	12/06
Global markets live: GSK, Tesla, Intel, General Motors, Gamestop...	11/06
Futures ease on rate-cut jitters ahead of inflation data, Fed meet	11/06	RE
Sage Therapeutics Says Phase 2 SURVEYOR Trial Met Primary Endpoint	11/06	MT
Sage Therapeutics says rare disease drug found to be safe in mid-stage study	11/06	RE
Sage Therapeutics, Inc. Announces Topline Results from the Phase 2 SURVEYOR Study	11/06	CI
Sage Therapeutics' rare disease drug meets main goal in mid-stage study	11/06	RE
Baird Initiates Sage Therapeutics With Neutral Rating, $15 Price Target	29/05	MT
Transcript : Sage Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM	15/05
Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained	26/04	MT
Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024	25/04
Earnings Flash (SAGE) SAGE THERAPEUTICS Reports Q1 Revenue $7.9M, vs. Street Est of $5.2M	25/04	MT
Sage Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Sage Therapeutics, Inc. Announces Not Standing for Re-Election of Board of Directors	25/04	CI
Sage Therapeutics, Inc. Announces Not Standing for Re-Election of Board of Directors	25/04	CI
TD Cowen Cuts Sage Therapeutics Price Target to $16 From $30, Maintains Buy Rating	18/04	MT

Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Sage Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

11.8 USD

Average target price

19.58 USD

Spread / Average Target

+65.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SAGE THERAPEUTICS, INC.	-45.55%	710M
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	127B
ARGENX SE	+24.16%	27.67B
BIONTECH SE	-20.17%	20.33B
GENMAB A/S	-16.06%	16.79B
BEIGENE, LTD.	-18.07%	15.63B
WUXI APPTEC CO., LTD.	-47.70%	14.65B
NEUROCRINE BIOSCIENCES, INC.	+11.92%	14.84B
SAREPTA THERAPEUTICS, INC.	+58.32%	14.43B
INSMED INCORPORATED	+149.98%	12.49B

Bio Therapeutic Drugs